Previous 10 | Next 10 |
2023-05-25 11:52:31 ET Shares of Annexon (NASDAQ: ANNX) were down more than 57% on Thursday after the company reported mixed results for an eye disease therapy late Wednesday. The clinical-stage healthcare company focuses on complement-mediated autoimmune, neurodegenerative, and...
2023-05-25 10:19:20 ET Annexon ( NASDAQ: ANNX ) shares lost ~58% in the morning hours Thursday to hit a new 52-week low after the company’s geographic atrophy candidate ANX007 failed in a Phase 2 trial. JPMorgan downgraded the biotech in reaction. Citing topline data ...
2023-05-25 10:04:19 ET Gainers: Absci ( ABSI ) +17% . Predictive Oncology ( POAI ) +10% . Cardio Diagnostics ( CDIO ) +8% . Ocean Biomedical ( OCEA ) +8% . HeartBeam ( BEAT ) +7% . Losers: Annexon ( ANNX ) -57% ....
2023-05-25 08:13:15 ET Biocept ( BIOC ) -41% on pricing $5.0M stock offering . QuantaSing Group ( QSG ) -32% . Digital Turbine ( APPS ) -31% after Q4 earning release . Annexon ( ANNX ) -23% . as geographic atrophy candidate fails in ph...
2023-05-24 17:32:31 ET Gainers: NVIDIA Corporation ( NVDA ) +22% . GSI Technology ( GSIT ) +16% . Nutanix ( NTNX ) +14% . Applied Digital ( APLD ) +12% . VNET Group ( VNET ) +10% . Losers: QuantaSing Group ( ...
ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through 12 months Reduction in rate of geographic atrophy lesion growth did not reach statistic...
2023-05-14 07:47:41 ET Summary Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. Th...
2023-05-08 17:02:03 ET Annexon Biosciences press release ( NASDAQ: ANNX ): Q1 GAAP EPS of -$52.00 misses by $51.48 . Cash and cash equivalents and short-term investments were $228.2 million as of March 31, 2023. Research and development (R&D) expenses: R&D ...
Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in 1H’23 Enrollment Expected to be Completed in Phase 3 Trial in Guillain-Barré S...
2023-04-23 08:01:40 ET Summary Two new Breakout Stocks for Week 17 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +58.9% YTD. Last week peak gains were in IMCR +16.5% and LTHM +7.1%. The Active ETF portfolio continues...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...